Trial Profile
Study of Erdheim-Chester disease patients with the MEK inhibitor cobimetinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2016
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary)
- Indications Erdheim-Chester disease
- Focus Therapeutic Use
- 02 Aug 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology